Screener
Halozyme Therapeutics HALO Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Income tax expense | 54,989 | 39,778 | 85,267 | 65,511 |
| Net income | $229,913 | $165,160 | $379,962 | $283,255 |
| Earnings per share | ||||
| Basic | $1.96 | $1.36 | $3.23 | $2.32 |
| Diluted | $1.90 | $1.33 | $3.11 | $2.26 |
| Weighted average common shares outstanding | ||||
| Basic | 117,274 | 121,343 | 117,707 | 122,274 |
| Diluted | 121,215 | 124,158 | 122,092 | 125,452 |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's shares (diluted)?
- Halozyme Therapeutics (HALO) reported shares (diluted) of 121.2M in Q2 2026.
- How has Halozyme Therapeutics's shares (diluted) changed year-over-year?
- Halozyme Therapeutics's shares (diluted) decreased by 2.4% year-over-year, from 124.2M to 121.2M.
- What is the long-term trend for Halozyme Therapeutics's shares (diluted)?
- Over 4 years (2021 to 2025), Halozyme Therapeutics's shares (diluted) has grown at a -4.2% compound annual growth rate (CAGR), from 589.7M to 497M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Halozyme Therapeutics's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude